
    
      Show that the correction of anemia by epoetin beta (NeoRecormon®) able to maintain a optimal
      dose of ribavirin (Copegus®). The study compares two therapeutic strategies : use or non-use
      of epoetin beta (NeoRecormon®) in patients infected by chronic hepatitis C and treated by
      combination therapy Peginterferon alfa-2a (Pegasys®) plus ribavirin (Copegus®). The main
      judgement criteria are :

        -  Sustained Viral Response (Week 72)

        -  Viral Response at the End of Treatment (Week 48)

        -  Quality of life

        -  Cumulative dose of ribavirin from D0-W24 and from W24-W48 periods

        -  Clinical and biological tolerance
    
  